Recent Trends in Nanocarrier Formulations of Actives Beyond Minoxidil and 5-Alpha Reductase Inhibitors in Androgenetic Alopecia Management: A Systematic Review

    Tanaya D. Khairnar, Gaurav S. Chavan, Meenaz M. Sayyed, Nayan A. Gujarathi, Abhijeet A. Aher, Yogeeta O. Agrawal, Tulshidas S. Patil
    TLDR Nanocarrier-based treatments show promise for better hair growth in androgenetic alopecia but need more research.
    This systematic review explores the potential of nanocarrier-based formulations for treating androgenetic alopecia (AGA) beyond the conventional minoxidil and 5-α reductase inhibitors. The review highlights the limitations of current treatments, such as frequent application and adverse effects, and discusses the advantages of nanocarriers, including improved drug stability, skin penetration, and targeted delivery. Various nanocarrier formulations of drugs like spironolactone, flutamide, and natural components were found to enhance hair follicle size and increase the anagen phase hair count. However, the review emphasizes the need for more extensive clinical trials to validate these findings and suggests that nanocarrier-based formulations offer a promising alternative for AGA management.
    Discuss this study in the Community →

    Research cited in this study

    38 / 38 results

    Related Community Posts Join

    3 / 3 results

    Related Research

    9 / 9 results